K36 Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.k36tx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate CancerMetastatic Castration-Resistant Prostate Cancer PatientsMetastatic Castration-resistant Prostate Cancer, mCRPCmCRPCmCRPC (Metastatic Castration-resistant Prostate Cancer)
- Interventions
- Drug: KTX-2001Drug: KTX-2001 + Darolutamide (NUBEQA®)
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- K36 Therapeutics, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT07103018
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- MyelomaMultiple MyelomaMyeloma Multiple
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- K36 Therapeutics, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT05651932
- Locations
- 🇺🇸
UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco, California, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
News
No news found